Back to search

Article

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?

2025-11-11

Abstract excerpt

<h4>Background: </h4> Metastatic colorectal cancer (mCRC) with TP53 gene mutations, which are commonly found in tumors that are microsatellite stable (MSS) and not prone to genetic errors seen in some cancers, is associated with aggressive cancer behavior and poor outcomes. While MSI-high (MSI-H, referring to high levels of gene instability) disease benefits markedly from PD-1–based immunotherapy (drugs that inhib...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8eb17137-136e-5e06-9780-ca4b77c3a212
DOI
10.20944/preprints202511.0710.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?DOI 10.20944/preprints202511.0710.v1
Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity
Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomesSemantic proximity
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?Semantic proximity
Conventional therapy induces tumor immunoediting and modulates the immune contexture in colorectal cancerSemantic proximity
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal CancerSemantic proximity
From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity
TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.Semantic proximity
Therapeutic landscape and future direction of metastatic colorectal cancer.Semantic proximity
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity
Select a neighboring publication to make it the new centre.